OrbiMed’s Pharvaris PHVS Stock Holding History

OrbiMed’s Portfolio PHVS Stock Details PHVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.1M	Hold	205,400	–	–	0.13%	92
2026 Q1	$5.8M	Hold	205,400	–	–	0.12%	90
2025 Q4	$5.7M	Buy	+205,400	New	+$4.95M	0.12%	90

Other funds holding PHVS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EFM

EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

OrbiMed's PHVS Position: Q2 2026 in Review

OrbiMed held its Pharvaris (PHVS) position steady in Q2 2026 at 205,400 shares worth $7.1M. The position accounts for 0.13% of the portfolio, ranked #92.

OrbiMed first reported a position in PHVS in Q4 2025 and has held it in 3 quarters since. 125 funds tracked by Wall St. Rank hold PHVS as of Q2 2026.

OrbiMed held 205,400 shares of Pharvaris worth $7.1M as of Q2 2026.
OrbiMed left its Pharvaris share count unchanged in Q2 2026.
Pharvaris made up 0.13% of OrbiMed's portfolio in Q2 2026, its #92 holding.
OrbiMed first reported a position in Pharvaris in Q4 2025 and has held it in 3 quarters since.
125 funds tracked by Wall St. Rank held Pharvaris as of Q2 2026.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.